Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
May 13, 2017
Prospective Oncotype DX® Genomic Prostate Score™ Test Data Presented at AUA and Published in Urology Establish Test's Ability to Increase Use and Persistence on Active Surveillance in Prostate Cancer Patients
Additional Oncotype DX GPS Test Study Results Represent First-ever Prospective Validation of a Tissue-based Molecular Marker in Prostate Cancer
May 12, 2017
Oncotype DX® Genomic Prostate Score™ (GPS) Test Predicts 10-year Risk of Prostate Cancer-specific Death and Metastases in Patients with Early-stage Disease
With New Data Presented at American Urological Association 2017 Annual Meeting, the GPS Test Becomes the Only Prostate Cancer Genomic Test Validated to Predict Both Near-term Adverse Pathology and Long-term Outcomes
May 10, 2017
Genomic Health to Present at Bank of America Merrill Lynch 2017 Health Care Conference
REDWOOD CITY, Calif. , May 10, 2017 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas on Wednesday, May 17, 2017 at 11:20 a.m. Pacific Time .
May 09, 2017
Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress
Delivered 7 Percent Increase in Test Volume; 4 Percent Increase in Revenue
Generated 17 Percent Test Growth and 29 Percent Revenue Growth Across International Markets
Continued to Accelerate Prostate Test Adoption with 40 Percent Volume Growth and 26 Percent Revenue Growth
Improved Earnings Per Share by $0.17
Conference Call Today at 4:30 p.m. ET
May 04, 2017
Genomic Health Announces Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of Oncotype DX® Genomic Prostate Score™ in Patients with Favorable Intermediate-risk Prostate Cancer
Once New LCD is Finalized, 80,000 Medicare Patients Total Will Be Eligible for Coverage
May 04, 2017
Genomic Health Announces Upcoming Presentation of Four Oncotype DX® Studies Including New Validation on Its Ability to Predict Prostate Cancer-specific Death and Metastases
Data from American Urological Association 2017 Annual Meeting Establishes Oncotype DX as First Genomic Prostate Cancer Test to Predict Both Near-term Adverse Pathology and Long-term Outcomes
May 02, 2017
Genomic Health to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017
REDWOOD CITY, Calif. , May 2, 2017 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 9 at 4:30 p.m. Eastern Time to discuss its first quarter 2017 financial results.  The call and webcast will follow the
Mar 29, 2017
Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients
Designated One of the 'Best Posters' by EAU, Results Highlight Expanded Value of Genomic Prostate Score™ in Assessing Risk and Long-term Outcomes in Patients Across Stages of Disease
Mar 24, 2017
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results
A Large Study Demonstrates Excellent Survival in Patients with Limited Nodal Involvement and Low Oncotype DX Breast Recurrence Score® Results
Mar 20, 2017
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy
New Findings Reinforce Breast Recurrence Score™ as Only Genomic Test to Guide Chemotherapy Decisions in Node-negative and Node-positive Disease and Support Growing Adoption of Test